Colinz Laboratories Ltd () News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{ "main_header": { "sid": 621096, "name": "Colinz Labs", "stock_name": "Colinz Labs", "full_name": "Colinz Laboratories Ltd", "name_url": "stocks-analysis/colinz-labs", "exchange": 0, "exchangecode": "", "primexch": 0, "country_id": 34, "currency": "INR", "cmp": "47.73", "chg": -2.27, "chgp": "-4.54%", "dir": -1, "prev_price": "50.00", "mcapval": "13.00 Cr", "mcap": "Micro Cap", "scripcode": 531210, "symbol": "", "ind_name": "Pharmaceuticals & Biotechnology", "ind_code": 4, "indexname": "India SENSEX", "isin": "INE923C01011", "curr_date": "May 06", "curr_time": "", "bse_nse_vol": "320 ", "exc_status": "Active", "traded_date": "May 06, 2026", "traded_date_str": "2026 05 06", "score": "", "scoreText": "", "Live": 0, "market_time": 0, "is_blur": 1, "is_blur_class": "blur-register-score-header", "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/colinz-labs-621096-0&utm_source=Spage_Header_Score", "mojoone": { "ismore": 0 } }, "news": { "results": [ { "title": "Colinz Laboratories Declines 1.68%: Downgrade and Mixed Q4 Results Shape the Week", "link": "https://www.marketsmojo.com/news/stocks-in-action/colinz-laboratories-declines-168-downgrade-and-mixed-q4-results-shape-the-week-3971730", "imagepath": "", "date": "2026-05-02 16:05:35", "description": " <div class=\"article-news-new\">\n <div class=\"article-container\">\n\n<div class=\"article-content\">\n <div class=\"highlight-box\">\n <h3>Key Events This Week</h3>\n <p><strong>27 Apr:</strong> Stock opens at Rs.45.00 after downgrade announcement</p>\n <p><strong>28 Apr:</strong> Mojo Grade downgraded to Strong Sell amid weak fundamentals</p>\n <p><strong>29 Apr:</strong> Stock rallies 4.00% on increased volume</p>\n <p><strong>30 Apr:</strong> Q4 FY25 results reveal profit surge but revenue stagnation; stock dips 3.64%</p>\n </div>\n\n <div class=\"stats-row\">\n <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.46.89</div></div>\n <div class=\"stat-item\"><div class=\"stat-label\">Week Close</div><div cla..." }, { "title": "Are Colinz Laboratories Ltd latest results good or bad?", "link": "https://www.marketsmojo.com/news/result-analysis/are-colinz-laboratories-ltd-latest-results-good-or-bad-3970719", "imagepath": "", "date": "2026-04-30 19:14:28", "description": "Colinz Laboratories Ltd's latest financial results for Q4 FY25 present a complex picture of operational performance. The company reported net sales of ₹1.75 crores, reflecting a sequential growth of 22.38% from the previous quarter and a year-on-year increase of 20.69%. This growth in sales is notable, especially considering the broader context of a 14.30% decline in annual sales for FY25 compared to FY24.\n\nIn terms of profitability, the net profit for Q4 FY25 was ₹0.17 crores, marking a significant sequential increase of 112.50%. The profit after tax margin improved to 9.71%, up from 5.59% in the previous quarter, indicating better operational efficiency and cost management. However, this improvement must be viewed cautiously, as it comes against a backdrop of declining annual revenues and a low return on equity (ROE) of 4.96%, which raises concerns about the company's ability to generate sustainable share..." }, { "title": "Colinz Laboratories Q4 FY25: Profit Surge Masks Underlying Revenue Concerns", "link": "https://www.marketsmojo.com/news/result-analysis/colinz-laboratories-q4-fy25-profit-surge-masks-underlying-revenue-concerns-3970201", "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/ColinzLaborator_quaterlyResult_3970201.png", "date": "2026-04-30 09:47:10", "description": "Colinz Laboratories Ltd., a micro-cap pharmaceutical formulations manufacturer, reported net profit of ₹0.17 crores for the quarter ended March 2026 (Q4 FY25), marking a 112.50% surge on a quarter-on-quarter basis from ₹0.08 crores in Q3 FY25. On a year-on-year basis, the company posted a modest 13.33% growth from ₹0.15 crores in Q4 FY24. However, this profit improvement comes against a backdrop of declining annual revenues and persistent operational challenges that raise questions about the sustainability of this performance." }, { "title": "Colinz Laboratories Downgraded to Strong Sell Amid Weak Fundamentals and Bearish Technicals", "link": "https://www.marketsmojo.com/news/stock-recommendation/colinz-laboratories-downgraded-to-strong-sell-amid-weak-fundamentals-and-bearish-technicals-3965791", "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/ColinzLaborator_mojoScore_3965791.png", "date": "2026-04-28 08:06:46", "description": "Colinz Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Sell to Strong Sell as of 27 Apr 2026. This shift reflects deteriorating technical indicators, stagnant financial trends, and weak fundamental quality, despite an attractive valuation. The stock’s recent performance and outlook suggest caution for investors amid challenging market conditions." }, { "title": "When is the next results date for Colinz Laboratories Ltd?", "link": "https://www.marketsmojo.com/news/result-analysis/when-is-the-next-results-date-for-colinz-laboratories-ltd-3958095", "imagepath": "", "date": "2026-04-22 23:15:56", "description": "The next results date for Colinz Laboratories Ltd is scheduled for April 29, 2026...." }, { "title": "Colinz Laboratories Ltd Upgraded to Sell on Technical Improvements Despite Weak Fundamentals", "link": "https://www.marketsmojo.com/news/stock-recommendation/colinz-laboratories-ltd-upgraded-to-sell-on-technical-improvements-despite-weak-fundamentals-3957188", "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/ColinzLaborator_mojoScore_3957188.png", "date": "2026-04-22 08:05:38", "description": "Colinz Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Strong Sell to Sell as of 21 April 2026. This change reflects a nuanced shift in the company’s technical outlook despite persistent fundamental challenges. The upgrade is primarily driven by a stabilisation in technical indicators, while valuation and financial trends continue to present a mixed picture for investors." }, { "title": "Colinz Laboratories Ltd Upgraded to 'Sell' as Technicals Improve Amidst Flat Financials", "link": "https://www.marketsmojo.com/news/stock-recommendation/colinz-laboratories-ltd-upgraded-to-sell-as-technicals-improve-amidst-flat-financials-3902238", "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/ColinzLaborator_mojoScore_3902238.png", "date": "2026-03-20 08:01:18", "description": "Colinz Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Strong Sell to Sell as of 19 Mar 2026. This change reflects a nuanced shift in the company’s technical outlook amid persistent fundamental challenges, prompting investors to reassess its near-term prospects." }, { "title": "Colinz Laboratories Downgraded to Strong Sell Amid Weak Fundamentals and Bearish Technicals", "link": "https://www.marketsmojo.com/news/stock-recommendation/colinz-laboratories-downgraded-to-strong-sell-amid-weak-fundamentals-and-bearish-technicals-3895830", "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/ColinzLaborator_mojoScore_3895830.png", "date": "2026-03-17 08:06:46", "description": "Colinz Laboratories Ltd has been downgraded from a Sell to a Strong Sell rating as of 16 Mar 2026, reflecting deteriorating technical indicators and persistent fundamental weaknesses. Despite a micro-cap status and an attractive valuation on price-to-book metrics, the company’s financial trends and technical signals have worsened, prompting a reassessment of its investment appeal." }, { "title": "Colinz Laboratories Ltd Valuation Shifts Signal Improved Price Attractiveness", "link": "https://www.marketsmojo.com/news/stocks-in-action/colinz-laboratories-ltd-valuation-shifts-signal-improved-price-attractiveness-3851973", "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/ColinzLaborator_valuationdot_3851973.png", "date": "2026-02-24 08:01:28", "description": "Colinz Laboratories Ltd has witnessed a notable shift in its valuation parameters, moving from a fair to an attractive rating, despite recent volatility in its share price and mixed returns relative to the broader market. This change reflects improved price-to-earnings and price-to-book value metrics, positioning the pharmaceutical and biotechnology firm as a potentially compelling investment within its sector." } ], "total": 606, "sid": "621096", "stock_news_url": "https://www.marketsmojo.com/news/colinz-laboratories-621096" }, "announcements": [ { "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication", "datetime": "30-Apr-2026", "details": "Dear Sir We have Publsihed our Outcome of Mar-26 Results as requred under Regulation 47(3) of SEBI(LODR) Regulations2015 in 1) FREE PRESS JOURNAL 2) NAV SHAKTI on 30-4-2026. Kindly take the note of the same. Director", "source": "BSE" }, { "caption": "Board Meeting Outcome for Disclosure Under Regulation 30 And Other Applicable Provisions Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015 (Listing Regulations)- Outcome Of The Board Meeting", "datetime": "29-Apr-2026", "details": "In terms of provisions of Regulation 30 (read with Part A of Schedule III) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 (Listing Regulations) this is to inform you that the Board of Directors at its Meeting held today i.e. 29th April 2026 has inter alia approved the Audited Financial Statements of the Company prepared as per Indian Accounting Standard (IND- AS) along with Auditors Report thereon for the quarter and financial year ended 31st March 2026; as recommended by the Audit Committee.", "source": "BSE" }, { "caption": "Integrated Filing (Financial) For The Quarter And Year Ended 31St March 2026", "datetime": "29-Apr-2026", "details": "Pursuant to SEBI Circular SEBI/HO/CFD/-POD-2024/185 dated 31-12-2024 read with BSE Circular No. 20250102-4 we are submitting herewith the Integrated Filing (Financial)for the Quarter and year ended 31-03-2026.", "source": "BSE" } ], "corporate_actions": [ { "img": "board-meeting.svg", "title": "BOARD MEETING", "msg": "<span>No</span> Upcoming Board Meetings", "data": [] }, { "img": "dividend.svg", "title": "DIVIDEND", "msg": "No <strong>Dividend</strong> history available", "data": [] }, { "img": "splits.svg", "title": "SPLITS", "msg": "No <strong>Splits</strong> history available", "data": [] }, { "img": "bonus.svg", "title": "BONUS", "msg": "No <strong>Bonus</strong> history available", "data": [] }, { "img": "rights-issues.svg", "title": "RIGHTS", "msg": "No <strong>Rights</strong> history available", "data": [] } ] }

Key Events This Week

27 Apr: Stock opens at Rs.45.00 after downgrade announcement

28 Apr: Mojo Grade downgraded to Strong Sell amid weak fundamentals

29 Apr: Stock rallies 4.00% on increased volume

30 Apr: Q4 FY25 results reveal profit surge but revenue stagnation; stock dips 3.64%

Week Open

Rs.46.89

Week Close

Read full news article

Are Colinz Laboratories Ltd latest results good or bad?

2026-04-30 19:14:28

Colinz Laboratories Ltd's latest financial results for Q4 FY25 present a complex picture of operational performance. The company reported net sales of ₹1.75 crores, reflecting a sequential growth of 22.38% from the previous quarter and a year-on-year increase of 20.69%. This growth in sales is notable, especially considering the broader context of a 14.30% decline in annual sales for FY25 compared to FY24. In terms of profitability, the net profit for Q4 FY25 was ₹0.17 crores, marking a significant sequential increase of 112.50%. The profit after tax margin improved to 9.71%, up from 5.59% in the previous quarter, indicating better operational efficiency and cost management. However, this improvement must be viewed cautiously, as it comes against a backdrop of declining annual revenues and a low return on equity (ROE) of 4.96%, which raises concerns about the company's ability to generate sustainable share...

Read full news article

Colinz Laboratories Q4 FY25: Profit Surge Masks Underlying Revenue Concerns

2026-04-30 09:47:10

Colinz Laboratories Ltd., a micro-cap pharmaceutical formulations manufacturer, reported net profit of ₹0.17 crores for the quarter ended March 2026 (Q4 FY25), marking a 112.50% surge on a quarter-on-quarter basis from ₹0.08 crores in Q3 FY25. On a year-on-year basis, the company posted a modest 13.33% growth from ₹0.15 crores in Q4 FY24. However, this profit improvement comes against a backdrop of declining annual revenues and persistent operational challenges that raise questions about the sustainability of this performance.

Read full news article

Colinz Laboratories Downgraded to Strong Sell Amid Weak Fundamentals and Bearish Technicals

2026-04-28 08:06:46

Colinz Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Sell to Strong Sell as of 27 Apr 2026. This shift reflects deteriorating technical indicators, stagnant financial trends, and weak fundamental quality, despite an attractive valuation. The stock’s recent performance and outlook suggest caution for investors amid challenging market conditions.

Read full news article

When is the next results date for Colinz Laboratories Ltd?

2026-04-22 23:15:56

The next results date for Colinz Laboratories Ltd is scheduled for April 29, 2026....

Read full news article

Colinz Laboratories Ltd Upgraded to Sell on Technical Improvements Despite Weak Fundamentals

2026-04-22 08:05:38

Colinz Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Strong Sell to Sell as of 21 April 2026. This change reflects a nuanced shift in the company’s technical outlook despite persistent fundamental challenges. The upgrade is primarily driven by a stabilisation in technical indicators, while valuation and financial trends continue to present a mixed picture for investors.

Read full news article

Colinz Laboratories Ltd Upgraded to 'Sell' as Technicals Improve Amidst Flat Financials

2026-03-20 08:01:18

Colinz Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Strong Sell to Sell as of 19 Mar 2026. This change reflects a nuanced shift in the company’s technical outlook amid persistent fundamental challenges, prompting investors to reassess its near-term prospects.

Read full news article

Colinz Laboratories Downgraded to Strong Sell Amid Weak Fundamentals and Bearish Technicals

2026-03-17 08:06:46

Colinz Laboratories Ltd has been downgraded from a Sell to a Strong Sell rating as of 16 Mar 2026, reflecting deteriorating technical indicators and persistent fundamental weaknesses. Despite a micro-cap status and an attractive valuation on price-to-book metrics, the company’s financial trends and technical signals have worsened, prompting a reassessment of its investment appeal.

Read full news article

Colinz Laboratories Ltd Valuation Shifts Signal Improved Price Attractiveness

2026-02-24 08:01:28

Colinz Laboratories Ltd has witnessed a notable shift in its valuation parameters, moving from a fair to an attractive rating, despite recent volatility in its share price and mixed returns relative to the broader market. This change reflects improved price-to-earnings and price-to-book value metrics, positioning the pharmaceutical and biotechnology firm as a potentially compelling investment within its sector.

Read full news article